Fundz
New|Fundz now works inside Claude2 min

Discover more near‑term opportunities with better event intelligence.

Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Aptadir Therapeutics raises €40M ($45M) in Seed financing to advance first-in-class demethylating medicines, led by 4BIO Capital.

PRIVATESep 29, 2026

Amount Raised

$45 Million

Round Type

Seed

MilanBiotechnologyHealth CareGeneticsTherapeutics

Investors

ExtendCdp Venture CapitalAngelini VenturesEvotec SEIndaco Venture PartnersXgen VentureCe VenturesKerna VenturesItalian Angels for BiotechClub Degli Investitori4BIO Capital

Description

Aptadir Therapeutics has closed its €40M Seed round to develop RNA inhibitor-based therapeutics. The funding was led by 4BIO Capital and includes follow-on participation from original investors. The funds will advance the company's pipeline for treating genetic conditions. Aptadir's technology targets gene silencing and aims to restore normal biological functions.

Company Information

Company

Aptadir Therapeutics

Location

Milan, Lombardy, Italy

About

Aptadir Therapeutics is a preclinical biotech company developing a new class of RNA therapeutics. The company focuses on creating investigational RNA inhibitors for treating intractable genetic conditions. Their technology aims to block aberrant DNA methylation, potentially restoring normal gene expression and biological function. Aptadir is committed to advancing innovative therapies for genetic disorders and cancer.

Fundz sees it the moment Aptadir Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Aptadir Therapeutics's next move

See what Strategic adds

Aptadir Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.